Category: Latest

Mesoblast Limited, (Nasdaq: MESO; ASX:), a global leader in allogeneic cellular medicines for inflammatory diseases has resubmitted its Biologics License Application (BLA) for approval of… [Read More]

Lexaria Bioscience (Nasdaq: LEXX), is charting a path to commercial success with its proprietary drug delivery technology, DehydraTECH™. The company closed out a year of milestone… [Read More]

Biopharmaceutical company, Quince Therapeutics (Nasdaq: QNCX), has sold its legacy small molecule protease inhibitor portfolio to Lighthouse Pharmaceuticals. As a result of the sale, Quince… [Read More]

Clinical-stage biotechnology company, Lipella Pharmaceuticals (LIPO) has released positive top line results from its Phase 2a clinical trial investigating a potential treatment for hemorrhagic cystitis…. [Read More]

 Lexaria Bioscience (Nasdaq:LEXX) has appointed the former President of GW Pharmaceuticals USA, Julian Gangolli, as a Strategic Advisor. Mr. Gangolli said: “The potential of Lexaria’s… [Read More]

Late-stage biopharmaceutical company, Spruce Biosciences (Nasdaq: SPRB), has announced an exclusive licensing agreement with Kaken Pharmaceuticals to develop and commercialize tildacerfont for congenital adrenal hyperplasia… [Read More]

The Player: OpenLocker Holdings, Inc. (OTCQB:OLKR)  OpenLocker Holdings is a technology platform for athletes and brands to redefine and unlock consumer and fan value. OpenLocker… [Read More]

 Neuroscience pioneer, Biogen, Inc. (Nasdaq: BIIB) has received FDA approval for lecanemab for the treatment of Alzheimer’s disease (AD). The FDA’s accelerated approval is based… [Read More]

Lexaria Bioscience, (Nasdaq: LEXX) has begun dosing subjects in an oral nicotine study that will compare DehydraTECH-nicotine pouch performance to existing leading brands ON!, manufactured… [Read More]